Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years
Insulet Presents Pivotal Extension Data for Preschool Children and Other Omnipod® 5 System Clinical Research at American Diabetes Association 82nd Scientific Sessions ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented new Omnipod® 5 Automated Insulin Delivery System … [Read more…]